Loading
Every dated change on the records linked to Mismatch-repair deficient (MSI-high) colorectal cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Untreated unresectable or metastatic MSI-high or dMMR colorectal cancer, with nivolumab
Untreated unresectable or metastatic MSI-high or dMMR colorectal cancer, with ipilimumab
Unresectable or metastatic MSI-high or dMMR colorectal cancer, with ipilimumab
3-year DFS 86.
A milestone in how this cancer is treated.
Previously treated MSI-high or dMMR endometrial, biliary, colorectal, gastric or small intestine cancer
Mismatch repair deficient or MSI-high tumours: NICE TA914 (20 September 2023) covers previously treated endometrial, gastric, small intestine, biliary and colorectal cancer and does not include pancreatic cancer
Colorectal cancer in 9 percent of participants on aspirin against 13 percent on placebo over ten years (hazard ratio 0.
PFS 16.
A milestone in how this cancer is treated.